69825-50-9

Upstream product

• 90-04-0 2-methoxy-phenylamine 
• 105-39-5 chloroacetic acid ethyl ester 
• 578-57-4 2-bromoanisole 
• 105-36-2 ethyl bromoacetate 
• 924-44-7 glyoxylic acid ethyl ester 
• 623-73-4 diazoacetic acid ethyl ester 

Downstream Products

• 94800-23-4 (2-methoxyphenyl)glycine 
• 112255-65-9 2-((2-methoxyphenyl)amino)acetohydrazide 
• 1391490-70-2 ethyl 8-methoxy-4-phenylquinoline-2-carboxylate 
• 86323-86-6 [(3-Mercapto-propionyl)-(2-methoxy-phenyl)-amino]-acetic acid 

Relevant academic research and scientific papers

Water-Involved Ring-Opening of 4-Phenyl-1,2,4-triazoline-3,5-dione for “Photo-Clicked” Access to Carbamoyl Formazan Photoswitches In Situ

Cyclic azodicarbonyl derivatives, particularly 4-phenyl-1,2,4-triazoline-3,5-dione (PTAD), commonly serve as arenophile, dienophile, enophile and electrophile. Perplexed by its instability in aqueous environment, there are few studies focused on the transient intermediate produced by hydrolysis of PTAD to achieve synthetic significance. Herein, we describe a “photo-click” method that involves nitrile imine (NI) from diarylsydnone to capture the diazenecarbonyl-phenyl-carbamic acid (DACPA) generated by water-promoted ring-opening of PTAD. DFT calculation reveal that H-bonding interactions between PTAD and water are vital to form DACPA which exhibited an umpolung effect during ligation by nature bond orbit (NBO) analysis. The ultra-fast ligation resulted in carbamoyl formazans, as a unique Z?E photo-switchable linker on target molecules, including peptide and drugs, with excellent anti-fatigue performance. This strategy is showcased to construct highly functionalized carbamoyl formazans in situ for photo-pharmacology and material studies, which also expands the chemistry of PTAD in aqueous media.

Preparation method of N-aryl glycine ester derivative

The invention relates to a preparation method of an N-aryl glycine ester derivative. The invention aims to solve the problems of complex steps and environmental pollution in the existing method for synthesizing the N-aryl glycine ester derivative. The preparation method comprises the following steps: dissolving an aryl primary amine compound, ethyl diazoacetate, a reaction aid and a photocatalystin an organic solvent at room temperature, uniformly mixing, reacting under a blue LEDs lamp, carrying out reduced pressure distillation to remove the solvent, and separating and purifying to obtain the product. The problems of high energy consumption, high cost and environmental pollution caused by high temperature, biocatalyst or metal organic framework required by the synthesis of the existingN-aryl glycine ester derivative are solved. A route for synthesizing the N-arylglycine ester derivative, which is green, efficient, mild in condition, simple in method, convenient to operate and highin yield, is found, and the method is applied to the field of organic synthesis.

Synthesis and biological potentials of some new 1,3,4-oxadiazole analogues

In continuation of our research to explore new antiproliferative agents, we report herein the synthesis and antiproliferative activity of two new series of N-(substituted phenyl)-5-aryl-1,3,4-oxadiazol-2-amine (4a–j) and N-{[5-aryl-1,3,4-oxadiazol-2-yl]me

Arylamino containing hydroxamic acids as potent urease inhibitors for the treatment of Helicobacter pylori infection

A novel series of aniline-containing hydroxamic acids were designed, synthesized and evaluated as anti-virulence agents for the treatment of gastritis and gastric ulcer caused by Helicobacter pylori. In vitro enzyme-based screen together with in vivo assays and structure?activity relationship (SAR) studies led to the discovery of three potent urease inhibitors 3-(3,5-dichlorophenylamino)–N-hydroxypropanamide (3a), 3-(2-chlorophenylamino)–N-hydroxypropanamide (3d) and 3-(2,4-dichlorophenylamino)–N-hydroxypropanamide (3n). Compounds 3a, 3d and 3n showed excellent urease inhibition with IC50 values 0.043 ± 0.005, 0.055 ± 0.008 and 0.018 ± 0.002 μM, and significantly depressed gastritis developing at the dose of 32 mg/kg b. i.d with eradication rates of H. pylori reaching 92.3, 84.6 and 100%, respectively. Preliminary safety studies (acute toxicity in mice) disclosed that 3a, 3d and 3n was well-tolerated in KM mice with LD50s of 2982.8, 3349.4 and 3126.9 mg/kg, respectively. Collectively, the data obtained in this study indicate that 3a, 3d and 3n, in particular 3n, could considered as promising candidates for the potential treatment of H. pylori caused gastritis and gastric ulcer, and hence merit further studies.

Preparation method of nerve regeneration amide medicine

The invention relates to a preparation method of a nerve regeneration amide medicine. The method is characterized in that the nerve regeneration amide medicine is prepared from o-methoxyaniline and ethyl glyoxalate through a four-step reaction, and the method concretely comprises the following steps: carrying out a reductive amination reaction on the raw materials comprising o-methoxyaniline and ethyl glyoxalate to obtain an intermediate I, reacting the intermediate with p-toluensulfonyl chloride to obtain an intermediate II, hydrolyzing the intermediate II to obtain an intermediate III, and reacting the intermediate III with 3-amino-4-methoxypyridine to obtain the final product. The preparation method has the advantages of low irritation in the synthesis reaction process, convenience in production and high molecule yield, and is a 2-[(2-methoxyphenyl)-(4-methylbenzenesulfonyl)]amino-N-(4-methoxypyridyl)-3-acetamide production method suitable for industrial production.

NH insertion reactions catalyzed by reusable water-soluble ruthenium(II)-hm-phenyloxazoline complex

A water-soluble Ru(II)-hm-pheox complex was efficiently catalyzed NH insertion of EDA with a broad class of amine derivatives in water/ether biphasic medium to deliver the biologically active precursors α-aminoester products with excellent yields (up to >99%). The products were separated by decantation and the catalyst was washed and reused several times (at least 8 times) without any specific loss of its catalytic activity. The plausible mechanism of the reaction was explained. Additionally, In case of ethylene diamine, the NH insertion product could be transformed to biological active piperazinone compound in high yield. The asymmetric version of this catalytic reaction is under investigation.

Iron-catalyzed oxidative tandem reactions with TEMPO oxoammonium salts: Synthesis of dihydroquinazolines and quinolines

A straightforward iron-catalyzed divergent oxidative tandem synthesis of dihydroquinazolines and quinolines from N-alkylanilines using a TEMPO oxoammonium salt as a mild and nontoxic oxidant has been developed. Fe(OTf) 2 was the Lewis acid cata

HETEROARYL COMPOUNDS, COMPOSITIONS THEREOF, AND USE THEREOF AS PROTEIN KINASE INHIBITORS

Provided herein are Heteroaryl Compounds having the following structure: (I) wherein R1, R2, L, X, Y, Z, Q, A and B are as defined herein, compositions comprising an effective amount of a Heteroaryl Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, metabolic conditions and conditions treatable or preventable by inhibition of a kinase pathway comprising administering an effective amount of a Heteroaryl Compound to a patient in need thereof.

Microwave-assisted synthesis of N-arylglycines: Improvement of sydnone synthesis

Reactions of anilines with ethyl bromoacetate under microwave irradiation have afforded N-arylglycines that are subsequently converted to their N-nitroso derivatives with a combination of silica chloride or periodic acid, wet SiO2 and sodium nitrite in CH2Cl2 with satisfactory yields. In the final step, the use of 1,3-dibromo-5,5-dimethylhydantoin (DBH) as a new and effective reagent for dehydration of N-nitroso-N-arylglycines to sydnones was successfully examined.

Piperidine derivatives with PAF antagonist activity

Compounds of general formula I and their salts and solvates are PAF antagonists and as such are useful in the treatment of various diseases or disorders mediated by PAF. Pharmaceutical compositions including these compounds and processes for their prepara